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Sequencing of DNA has never been easier. It is now perfectly possible to sequence an 
individual’s entire genome from a few micrograms of DNA, obtained from peripheral blood 
or elsewhere. The cost of sequencing has also fallen dramatically. The biggest hurdle is now 
in making sense of the data. Variation in DNA sequence contributes a large part of the 
phenotypic differences between individuals. However most of the variation occurs in non-
coding DNA; the overwhelming majority of which we cannot yet interpret. Variation within 
genes is much better understood; but even here not everything is as simple as it might 
seem. 
 
“Simple” genetics might consider highly penetrant alleles, causing Mendelian phenotypes, 
be they dominant or recessive. That is to say, that those with a given genotype have highly 
predictable manifestations. At the other end of the spectrum are relatively common 
variants that have been associated with particular diseases. Win the latter case many 
unaffected individuals will have the risk allele; although it is more common in those with the 
disease phenotype. In between these extremes are variants which are identified as making 
intermediate contributions to the phenotype in question. This later group might be 
considered “contributory”, “predisposing” or even “modifiers” of a condition. In truth 
however, many variants contribute to every disease, it is just the extent of their 
contribution that varies. There are probably no fully penetrant alleles, or indeed any 
discrete categories of contribution. Worse still, because of the effect of other variants, and 
non-genetic factors, one variant might contribute more in one individual than in another. 
  
 
All of this makes the interpretation of genetic variants surprisingly complex. There has been 
a rapid growth in websites and software designed to help us interpret genetic variation. 
There have been guidelines, most notably from the American College of Medical Genetics 
and Genomics (ACMG) (1), to help us. The software tools are only as good as the 
information available to them; this is mostly from the public domain, though some have 
their own databases. The ACMG guidelines are now widely employed; though they probably 
increase consistency, more than improving accuracy. To date all these tools have still been 
directed at highly penetrant or Mendelian models of disease. 
 
We understand variation in some genes better than others. The liver disease gene with the 
best understood variation is probably HFE, underlying genetic haemochromatosis. The 
contributions to disease of the three major variants have been very well characterised(2). 
The risks associated with all combinations of these alleles has been defined. However this 
doesn’t predict those who will get haemochromatosis; only those with increased risk. In 
more recent times a common variant in PNPLA3 has been associated with both NAFLD and 
alcohol-associated liver disease. However in this case the penetrance and the contribution 
to disease are so low that it is of little use in making a diagnosis, though it may be of use in 
predicting response to treatment (3). 
 
A growing list of genes have been associated with cholestatic liver disease. It is now 19 years 
since the first three were described (4-6). This means that considerable numbers of patients 
have been sequenced for these genes, and some prediction of the contribution of genetic 
variants can be made. Merely collecting genetic data is of little value however, it is only 
when this is combined with high quality phenotypic data can we begin to learn. In this issue 
Keitel and colleagues (7) describe 154 variations in ATP8B1, ABCB11 and ABCB4 in 427 
individuals, all suspected of having genetic cholestasis. In this cohort of patients several 
previously described disease-causing variants were found. Several novel putatively disease-
causing variants were identified. These are important additions to the ever-growing 
catalogue of variants for which there is good evidence of major pathological effect. Protein 
truncating mutations form the minority, though their pathogenicity is generally clear. 
Consensus splice site mutations, affecting the first or last 2 bases of an intron are also 
generally easy to classify as detrimental. The current difficulty really lies with missense 
changes. Such variants are frequently thought of as changes in the amino acid sequences. In 
truth they are alterations in genomic DNA. If transcription occurs normally they become 
changes in pre-mRNA. As such they may affect splicing and processing into mRNA. Only if 
these steps are overcome can such changes become variants in the polypeptide (8). 
 
The molecular consequence of variants in the amino acid sequence of proteins can be 
analysed in several ways. The most powerful evidence in favour of pathogenicity is the 
observation of such a change, in trans, with another known pathogenic change. All other 
interpretations of function are open to criticism. Commonly applied observations include 
the degree of evolutionary conservation of the same protein, and between similar proteins, 
at both the nucleotide and amino acid level. The functional change predicted by in silico 
models can be helpful, but the tools available still lack enough data. In vitro models can be 
used to look at all the stages of mRNA and protein production, and function. However no in 
vitro experiment is perfect, yet! Keitel and colleagues combine the widely available 
  
predictive tools, along with less used computer modelling. Future patients will tell us which 
have worked best, and the determined pathogenicity of known variants will increase or 
decrease accordingly. 
 
Previous studies have shown that common variants in these genes are over represented in 
patients with “acquired” cholestasis. Of course such patients probably harbour variants 
which impair the quantity or function of the gene/protein to a lesser degree than the better 
described “disease-causing” mutations. The idea that “disease-predisposing” or “modifier” 
variants are in fact similar is highlighted by data in the current paper. Some common 
variants appear to be more common than is seen in the general population; in patients with 
no other mutations, where they would be predisposing or in patients with pathogenic 
mutations, where they would be modifiers. In all experiments examining allele frequencies 
the biggest problem is control data. The bigger, and better matched, the control set is the 
more credible are any differences in frequency between them and patients. The data in 
Keitel’s paper compare the observed frequencies with those seen in the Gnomad database 
(9). This is currently the largest publically-available set of allele frequencies. It is in fact an 
aggregation of data from other projects, and includes information from 138,000 individuals. 
The presence of a variant in such a large dataset does not exclude it from being highly 
pathogenic, as many are very rare. On the other hand many variants have very different 
frequencies in different populations. The data presented in Gnomad are broken down into 7 
large groups and “others”. Brief inspection will show that some populations have been 
much more extensively investigated than others; e.g. Ashkenazi Jews and Finns. Europeans 
make up almost half the chromosomes sequenced, though we do now have much better 
data on individuals from other regions of the world than we had even one year ago. Keitel 
compares the overserved frequencies with those seen in the entire Gnomad dataset, and 
with those seen in Europeans, as that was thought to be the origin of most of their patients. 
As the quantity and quality of control data grows this and previous analyses, based on 
comparison with controls, will need re-examination. 
 
DNA sequencing is now increasingly cheap and easy. Data analysis however remains 
complex. Variants in genes should be thought of as contributing to the phenotype; the most 
difficult decision in to what extent. The sequencing being carried out today, be it in patients 
and controls, will help build the datasets that will inform future research and, more 
importantly, diagnosis. 
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